Episode 527: Pfizer CFO Dave Denton on Oncology, Obesity, and Pfizer’s Next Growth Cycle

About this episode

Pfizer CFO Dave Denton discusses the company's post-COVID transition and strategic investments for sustainable growth.

Pfizer CFO Dave Denton goes Inside the ICE House to discuss how the company is navigating its post‑COVID transition and positioning itself for a return to sustainable growth later this decade. He details Pfizer’s major strategic investments in oncology and metabolic health, including the Seagen and Metsera deals, and explains how proven platforms, global scale, and financial discipline are central to those moves. Denton also shares how execution, patient‑centric innovation, and emerging technologies like AI are shaping the next chapter of Pfizer’s growth story.

People in this episode

Guest: Dave Denton

Topics covered

• oncology
• obesity
• sustainable growth
• post-COVID transition
• strategic investments
• patient-centric innovation
• emerging technologies

Keywords

• Pfizer
• Dave Denton
• oncology
• obesity
• growth cycle
• AI
• strategic investments

Mentioned in this episode

Organizations: Pfizer, Seagen, Metsera

More episodes of Inside the ICE House

• Episode 539: Flutter CEO Peter Jackson on World Cup Betting, Global Impact, and U.S. Growth · June 12, 2026 · 27 min
• Market Storylines: Tech Rotation, Iran Volatility + Small Cap Strength · June 11, 2026 · 7 min
• ETF Central: Milliman Principal & Managing Director Adam Schenck · June 10, 2026 · 41 min
• Episode 538: Link Logistics CEO Luke Petherbridge on Supply Chains, Speed and Last-Mile Demand · June 8, 2026 · 30 min
• Market Storylines: Crypto Weakness, AI Momentum + Iran Headlines Shift · June 5, 2026 · 8 min
• May 2026 Rewind: "Best of" Inside the ICE House · June 4, 2026 · 13 min